Mylan NV Pays $7.2 Billion for Meda AB, Here's Why
57:34 - Mylan NV agreed to buy Meda AB for about $7.2 billion in cash and stock, adding the Swedish company’s specialty drug products and European operations. CEO Heather Bresch speaks about the deal on "Bloomberg ‹GO›." (Source: Bloomberg)
TD Ameritrade's Lessons Learned From Robo-Advisors
How Are Retail Investors Trading in Volatile Markets?
Kyle Bass Warns of Huge Losses for Chinese Banks
Please upgrade your Browser
Your browser is out-of-date. Please download one of these excellent browsers: